NovImmune: Late-breaking abstract at ASH supports evidence on transformative first-ever treatment in primary HLH

Swedish Orphan Biovitrum AB (publ) (Sobi ) (http://www.sobi.com/) and Novimmune SA (http://www.novimmune.com/) are pleased to announce that the abstract "Safety and efficacy of emapalumab in paediatric patients with primary hemophagocytic lymphohistiocytosis" was accepted as a late-breaking abstract at the 60th Annual Meeting of the American Society of Hematology in San Diego, California, 1-4 December 2018, for oral presentation. The presentation of the data will be given on Tuesday, 4 December, by the first author Professor Franco Locatelli, Head of the Department of Onco-Haematology,